Journal Article

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study

Tanaka, Kenichi, Okada, Yosuke, Tanaka, Yoshiya, Tokutsu, Akemi

2022

Overview

Real-world data comparing the effectiveness of various glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM) are limited. We investigated the clinical effectiveness of liraglutide and dulaglutide in Japanese T2DM in a real-world setting. This retrospective study included 179 patients with T2DM who were treated with GLP-1 RA for at least 12 months (liraglutide, n = 97; dulaglutide, n = 82). We used stabilized propensity score-based inverse probability of treatment weighting (IPTW) to reduce selection bias and confounding by observed covariates. Changes in glycated hemoglobin (HbA1c) at the end of the 12-month treatment were evaluated. After adjustment by stabilized propensity score-based IPTW, no significant differences were observed in patient characteristics between the liraglutide and dulaglutide groups. HbA1c was significantly lower at 12 months in both groups (liraglutide, 8.9 to 7.4%; dulaglutide, 8.7 to 7.5%). Multivariate linear regression analysis showed no differences in the extent of changes in HbA1c at 12 months between the two agents. High baseline HbA1c, the addition of GLP-1 RA treatment modality, and in-hospital initiation of GLP-1 RA treatment were identified as significant contributing factors to HbA1c reduction. The effects of liraglutide and dulaglutide on lowering HbA1c levels at 12 months were comparable in a real-world setting.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 692/163 / 692/163/2743 / Aged / Antidiabetics / Biomarkers - blood / Blood Glucose - drug effects / Blood Glucose - metabolism / Comparative Effectiveness Research / Diabetes / Diabetes mellitus (non-insulin dependent) / Diabetes Mellitus, Type 2 - blood / Diabetes Mellitus, Type 2 - diagnosis / Diabetes Mellitus, Type 2 - drug therapy / Female / GLP-1 receptor agonists / Glucagon / Glucagon-like peptide 1 / Glucagon-Like Peptide-1 Receptor - agonists / Glucagon-Like Peptides - adverse effects / Glucagon-Like Peptides - analogs & derivatives / Glucagon-Like Peptides - therapeutic use / Glycated Hemoglobin A - metabolism / Glycemic Control - adverse effects / Hemoglobin / Humanities and Social Sciences / Humans / Hypoglycemic Agents - adverse effects / Hypoglycemic Agents - therapeutic use / Immunoglobulin Fc Fragments - adverse effects / Immunoglobulin Fc Fragments - therapeutic use / Incretins - adverse effects / Incretins - therapeutic use / Japan / Liraglutide - adverse effects / Liraglutide - therapeutic use / Male / Middle Aged / multidisciplinary / Patients / Recombinant Fusion Proteins - adverse effects / Recombinant Fusion Proteins - therapeutic use / Regression analysis / Retrospective Studies / Science / Science (multidisciplinary) / Time Factors / Treatment Outcome